China Health Holding, Inc., a development stage pharmaceutical company with the goal of becoming a leading developer, manufacturer, marketer and distributor of pharmaceutical and natural medical drugs in China and worldwide, announced it has signed a binding memorandum of understanding (MOU) with the Beijing Jifatang Chinese Medicine Research & Development Institution for New Drugs R&D Strategic Alliance, Collaboration, and Partnership.

The 10-year agreement will allow China Health Holding to take full advantage of the institution's groundbreaking R&D to treat conditions ranging from diabetes and cancer to neurological and cardiovascular disorders.

This R&D partnership will strengthen China Health Holding's ability to attract and retain R&D talent in the People's Republic of China. It also will enable us to develop more new TCM-Based pharmaceutical drugs that complement the portfolio we are assembling from our ongoing acquisition of pharmaceutical firms in China. This new memorandum of understanding with Beijing Jifatang Chinese Medicine Research & Development Institution demonstrates our commitment to the expansion of China Health Holding's R&D, which is a critical part of our strategic plan along with the acquisition process.

Under the terms of the MOU, China Health Holding will be granted the right of first refusal and exclusive right for any new intellectual property developed by Beijing Jifatang Chinese Medicine Research Institution for a period of 10 years beginning January 2007. In return, China Health Holding will issue 200,000 common shares of its restricted common stocks to the Beijing Institution.

The move is the latest in a series of agreements and acquisitions aimed at establishing the China Health Holding as a leader in the fast-growing Chinese medical and pharmaceutical industry. In 2005, Traditional Chinese Medicine ("TCM") accounted for more than 25 percent of China's overall medical spending, resulting in total sales of approximately $12.2 Billion USD.

Source:未知